Revolution Medicines has delivered a very strong share price run over the past few years, yet its valuation checks lean expensive. This sets up a clear tension between recent returns and what the broader metrics say about value.

• Revolution Medicines has returned about 6.4x over the past 3 years. This places the stock in a very strong performance bracket and raises the bar for what future progress needs to justify.
• The FDA review of daraxonrasib following positive survival data can support high growth expectations. However, execution risk around regulatory outcomes, competitive treatments and eventual commercial uptake may weigh on how much investors are willing to pay for that story.
• With a value score of 2 out of 6, Revolution Medicines does not screen as a clear bargain on the wider set of valuation checks.

The issue now is whether the current price of Revolution Medicines already reflects most of the good news, or if investors are still being compensated for the risks ahead.

Has Revolution Medicines Run Too Far on Book Value?

P/B is a reasonable lens for Revolution Medicines because it is still loss making and investors are anchoring more on its research pipeline and balance sheet rather than on near term earnings. On this measure, the stock trades at a P/B of 26.8x, compared with an industry average of 2.5x for biotechs and a peer group average of 10.3x.

The gap is very wide, and the model heavily penalises Revolution Medicines for its current losses and risk profile, so the high multiple reads more as a warning flag than as something that can be justified by simple comparison to the sector. Following the surge on positive daraxonrasib news and regulatory momentum, the valuation already places Revolution Medicines at a steep premium to what investors are paying for many other biotech stocks with positive book value and similar business risks.

On the P/B multiple, Revolution Medicines currently screens as overvalued compared with both its industry and peer benchmarks.

The Revolution Medicines Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Revolution Medicines take the valuation tension above and turn it into clear scenarios about what would need to happen to growth, margins and earnings for Revolution Medicines' stock to be worth materially more or less than today. Each scenario links a fair value to a specific mix of potential catalysts and risks, so you can track over time which version of the story appears to be unfolding on Simply Wall St's Community page.

Community views on Revolution Medicines sit far apart, with one side leaning into the RAS oncology upside and the other focused on the cost and execution load.

Bull case: 7% undervalued

"Three separate RAS(ON) inhibitors with breakthrough therapy designations and a fourth in the clinic, together with a fifth class targeting resistance, position the company to participate in successive treatment lines and combinations…"

Bear case: 25% overvalued

"Although the company has access to substantial liquidity with US$2.03b in cash and investments and up to US$1.75b of remaining committed capital from Royalty Pharma, GAAP operating expenses guided to US$1.6b to US$1.7b for 2026 signal heavy ongoing spend…"

Do you think there's more to the story for Revolution Medicines? Head over to our Community to see what others are saying!

The Bottom Line

For Revolution Medicines, the current setup is all about how much confidence you have that the RAS oncology pipeline can ultimately justify a premium price tag. Market multiples point to an overvalued stock, especially given the extreme gap between its P/B ratio and sector peers, and broader valuation checks remain weak. That does not settle the debate, but it means the story now leans more on clinical, regulatory and commercial execution than on any obvious mispricing. The key question from here is whether future data and approvals can sustain today’s expectations without the valuation needing to cool first.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.